Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Michael Bukhalo MD

Neither a doctor nor a teaching hospital

Research payments

$1,494,778

216 payments

Through program year 2025, Michael Bukhalo MD is reported as receiving $1,494,778 in research payments, across 216 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $184,329 38
2024 Research $675,123 58
2023 Research $206,171 39
2022 Research $381,104 58
2021 Research $18,594 10
2020 Research $29,456 13

Breakdown

Who paid Research payments · program years 2020–2025
  1. Janssen Research & Development, LLC $1,149,879 152 payments
  2. AbbVie, Inc. $255,443 55 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $70,926 3 payments
  4. Galderma Laboratories, L.P. $18,530 6 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $423,322 46 payments
  2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $223,813 25 payments
  3. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf $193,034 23 payments
  4. A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $151,108 7 payments
  5. A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) $124,574 19 payments
  6. A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. $94,189 18 payments
  7. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $70,926 3 payments
  8. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $69,434 16 payments
  9. A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis $25,231 7 payments
  10. A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants $23,176 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record